MYB NewsBusiness News
Markets
Business · 1 min read

Johnson & Johnson buys Ollin Biosciences for $2.2 billion

Johnson & Johnson bought the Austin drug developer to grow its eye medicine business. It may pay another $1.125 billion if certain goals are met.

Gloved hands fill a capsule-making tray in a pharmaceutical plant.

Johnson & Johnson announced on November 16 that it agreed to buy Ollin Biosciences, a clinical-stage drug company based in Austin, Texas. The initial price is $2.2 billion. The company may pay an additional $1.125 billion if the drug hits certain regulatory and sales goals.

Ollin Biosciences develops treatments for serious eye diseases. The deal adds an investigational drug called OLN324 to the company's pipeline. This drug targets retinal diseases like wet age-related macular degeneration.

Blackstone Life Sciences will provide $750 million to fund the final Phase 3 testing of the drug. In exchange, Blackstone Life Sciences will receive future payments and royalties. Johnson & Johnson expects to close the deal by the end of 2026.

Shares of Johnson & Johnson rose by about $2 to around $288.00 on November 16. The stock has gained 39.3% this year.

About Johnson & Johnson

U.S. multinational manufacturer of pharmaceuticals and medical devices

Share price
$270.47+1.25% last trading day
Revenue
$88.8 billiona year, 2024
Employees
138,2002026
Founded
1886by Robert Wood Johnson I
Based in
New Brunswick
Chief executive
Joaquin Duato
Owned by
ShareholdersNYSE: JNJ

From Wikipedia and Yahoo Finance. Figures can be a year or two old.

Reported and written by MYB News.

Figures as reported by ROI-NJ.

Sources
Comment

Comments

Talk business and keep it civil. A complaint about a private person or a local business goes to them first, not here.